Avita Medical Inc is a regenerative medicine company that focuses on developing products for wound care and tissue repair through its innovative skin regeneration technology. The company's flagship product utilizes a proprietary process that enables the harvesting and application of a small sample of a patient's own skin cells to promote healing for various types of wounds, burns, and other skin injuries. By leveraging the body's natural regenerative capabilities, Avita Medical aims to improve patient outcomes and enhance the recovery process, positioning itself as a leader in advanced therapeutic solutions within the healthcare sector. Read More
VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA). The award, the ABA’s highest honor, recognizes individuals whose enduring contributions have advanced burn care, research, and education. Professor Wood was presented with the award during a ceremony at the ABA 2026 Annual Meeting.
VALENCIA, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thickness wounds. The results demonstrated statistical superiority (p<0.001) versus a literature-derived benchmark, based on the lower bound of the 95% confidence interval (28 days). The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients.
VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company’s wound care portfolio.
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O’Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).
VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025.
VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations include the first surgeon-reported integrated use of all three AVITA Medical technologies – RECELL, PermeaDerm, and Cohealyx – in individual patient cases, as well as clinical and tissue-level findings from separate studies evaluating PermeaDerm and Cohealyx.
VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical’s website at: https://ir.avitamedical.com/events-and-presentations
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025.
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time.
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on November 12, 2025, at 2:00 p.m. U.S. Pacific Standard Time (November 13, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2025.
Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations
VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.
